Teduglutide (Gattex, Revestive)
FDA-approved GLP-2 receptor agonist used in short bowel syndrome to enhance intestinal absorption.
At a glance
What it is: FDA-approved GLP-2 receptor agonist used in short bowel syndrome to enhance intestinal absorption..
Primary research applications:
- Short bowel syndrome (SBS) requiring parenteral support
Editorial summary: Teduglutide is the first GLP-2 receptor agonist approved as a therapeutic — a molecularly clean example of peptide drug design. In short bowel syndrome, it reduces dependence on parenteral nutrition. Its precise indication and demonstrated outcomes data make it a model peptide therapeutic outside the GLP-1 / obesity space.
- Class / structure
- 33-amino-acid synthetic GLP-2 analog (Ala→Gly substitution at position 2)
- Half-life
- ≈ 1.3 hours (subcutaneous)
- First described
- Late 1990s
- Regulatory status
- FDA-approved (Gattex 2012)
What is Teduglutide?
Teduglutide is a synthetic 33-amino-acid analog of glucagon-like peptide-2 (GLP-2), a hormone secreted by intestinal L-cells in response to nutrient ingestion. It activates the GLP-2 receptor on intestinal subepithelial myofibroblasts and other cells, driving trophic effects on intestinal mucosa.
Discovery and development
Teduglutide was developed by NPS Pharmaceuticals and approved by the FDA in 2012 as Gattex for adults and pediatric patients aged one year and older with short bowel syndrome (SBS) requiring nutritional support. Its design — an Ala→Gly substitution at position 2 of native GLP-2 — confers resistance to DPP-4 cleavage and extends half-life sufficiently for once-daily subcutaneous dosing.
Mechanism of action
GLP-2 receptor activation increases villus height, crypt depth, and intestinal absorptive surface area. It also slows gastric emptying and reduces intestinal motility. In short bowel syndrome — where surgical resection has reduced absorptive capacity — these trophic effects translate to clinically meaningful reductions in parenteral nutrition requirements.[1]
Pharmacokinetics
Subcutaneous bioavailability is approximately 88%. Plasma half-life of ~1.3 hours (longer than native GLP-2 but still short relative to GLP-1 analogs) supports once-daily dosing for the slow-onset trophic effects on intestinal mucosa.
What the research shows
The peer-reviewed literature on Teduglutide is summarized below across two tiers: human research (the highest standard), and preclinical / emerging research (animal models and early-stage human work).
Claims and the evidence behind them
This table summarizes commonly discussed claims and how the published evidence weighs in. The aim is clarity — supported claims, claims that look promising but need more data, and claims that outrun the science.
| Claim | What the evidence shows | Verdict |
|---|---|---|
| Reduces parenteral nutrition requirements in SBS | STEPS trial | Supported |
| Increases intestinal absorptive surface area | Histologic and clinical evidence | Supported |
| Useful as a general "gut healing" peptide | Outside SBS, evidence is limited and indication-specific | Mixed |
Reported user experiences
How the research describes administration
Once-daily subcutaneous injection. The treatment is administered under specialist supervision in centers experienced with SBS management.
Editorial note
Administration details above describe how the peptide is given in published studies. We summarize this for educational completeness — these descriptions are not protocols, dosing recommendations, or instructions for personal use. Decisions about treatment require an appropriately licensed clinician.
Safety considerations and open questions
The takeaway
Teduglutide is a clean example of how a precise understanding of incretin / enteroinsular biology can produce a focused, life-changing therapeutic. It is the most clinically advanced GLP-2 agonist and a useful counterpoint in any discussion of how peptide drugs find their place in narrow but important indications.
Frequently asked questions
Is teduglutide a GLP-1 drug?
No. It is a GLP-2 analog. GLP-1 and GLP-2 are different peptides with different receptors and different physiologic roles, though both are products of the proglucagon gene.
Is teduglutide used for general "gut healing"?
It is FDA-approved specifically for short bowel syndrome with intestinal failure. Use outside that indication is not supported by current trial evidence.
References
- Drucker DJ, Yusta B. Physiology and pharmacology of the enteroendocrine hormone glucagon-like peptide-2. Annu Rev Physiol. 2014;76:561-583. https://pubmed.ncbi.nlm.nih.gov/24161075/
- Jeppesen PB, et al. Teduglutide reduces need for parenteral support among patients with short bowel syndrome with intestinal failure (STEPS). Gastroenterology. 2012;143(6):1473-1481. https://pubmed.ncbi.nlm.nih.gov/22982184/